WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a RNA interference (RNAi) company focused on developing breakthrough oncology therapeutics, today announced that Kyowa Hakko Kirin Co., Ltd. (KHK) (TSE: 4151) has elected to advance the second therapeutic oncology candidate from the research to development stage. The achievement of this milestone triggers a $5 million payment from KHK to Dicerna.
